USANA Health Sciences
The 10-second takeaway
For the quarter ended March 31 (Q1), USANA Health Sciences beat expectations on revenues and crushed expectations on earnings per share.
Compared with the prior-year quarter, revenue grew and GAAP earnings per share increased significantly.
Margins increased across the board.
USANA Health Sciences chalked up revenue of $154.1 million. The four analysts polled by S&P Capital IQ predicted revenue of $143.9 million on the same basis. GAAP reported sales were 7.4% higher than the prior-year quarter's $143.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.90. The five earnings estimates compiled by S&P Capital IQ predicted $0.69 per share. GAAP EPS of $0.90 for Q1 were 29% higher than the prior-year quarter's $0.70 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 82.3%, 20 basis points better than the prior-year quarter. Operating margin was 13.5%, 150 basis points better than the prior-year quarter. Net margin was 8.9%, 100 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $155.2 million. On the bottom line, the average EPS estimate is $0.92.
Next year's average estimate for revenue is $623.7 million. The average EPS estimate is $3.67.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 200 members out of 380 rating the stock outperform, and 180 members rating it underperform. Among 126 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give USANA Health Sciences a green thumbs-up, and 79 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on USANA Health Sciences is hold, with an average price target of $41.20.
Over the decades, small-cap stocks like USANA Health Sciences have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
- Add USANA Health Sciences to My Watchlist.